Plant-based Covid-19 vaccine developer Medicago laying off 60+ at North Carolina plant

27 Oct 2022
endpts.com
VaccineCollaborate
Medicago had been looking at, among other things, a plant-based vaccine for Covid-19. But those plans aren’t going in the direction Medicago wanted to. Medicago’s US subsidiary Medicago USA filed a WARN notice Wednesday in North Carolina, saying that 62 employees at its manufacturing facility in Durham will be out of a job within two months. Medicago CEO Toshifumi Tada, who just recently joined the biotech earlier this year, told Endpoints News via email that: Tada became CEO back in May, transitioning from head of vaccine business development at Medicago’s parent company, Mitsubishi Tanabe Pharma. This is the newest development for the vaccine maker after the WHO balked at Medicago’s Covid-19 vaccineCovid-19 vaccine earlier this year. Medicago partnered with GSK to use one of GSK’s adjuvants to boost immune response. The international organization balked because of the biotech’s ties to Big Tobacco, more specifically Philip Morris International, the maker of Marlboro cigarettes and a part-owner of Medicago. Many biotechs — and several pharmas — have had to pull out the trimmers in 2022 because of budget constraints and R&D mishaps. Biotechs include Zosano, which now filed for bankruptcy and is selling off all of its assets , after doing two rounds of layoffs in order to try and stay afloat. Or more recently Ambrx, announcing plans last week to cut 15% of staff in a bid to extend cash resources. On the pharma side, AbbVie recently laid off 100 in California, right at the same time as Bristol Myers let go of 260 staffers as it was looking to integrate Turning Point Therapeutics into the fold. Biogen also started laying off people in light of Aduhelm’s failure back in March . A senior official within the company told Endpoints at the time that more than 100 individuals have been laid off so far, including two-thirds of the Alzheimer’s commercial team and all of the Alzheimer’s field leaders.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.